drugset / Trial / NCT03559439
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label phase 1 study to determine the safety and efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with CD19+ B cell malignancies.
Timeline
- Start
- 2018-04-24
- Primary completion
- 2021-11-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | CD19 CAR-T | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CD19 CAR-T | Cell therapy | 6e+06 cells/kg | Intravenous |